Drugs / EP2006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01519700 | Dec 2011 → Jun 2013 | breast cancer, neutropenia | Sandoz | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-12-08 | Novartis Pharmaceuticals | Results Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine novartis.com ↗
The Phase I study, conducted in healthy volunteers, confirmed that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of PK, PD, safety and immunogenicity profiles[1]. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-12-08 | Novartis Pharmaceuticals | Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP2006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01519700 ↗ |
| Modality | Protein / enzyme biologic | “Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III,” PMID 26122726 ↗ Jun 2015 |